✦ LIBER ✦
Tanezumab, an Anti-Nerve Growth Factor (NGF) antibody, for the treatment of chronic low back pain (CLBP) – a randomized, controlled, double-blind, phase 2 trial
✍ Scribed by N. Katz; D. Borenstein; C. Birbara; C. Bramson; M. Nemeth; M. Smith; M. Brown
- Book ID
- 118476377
- Publisher
- Elsevier Science
- Year
- 2009
- Tongue
- English
- Weight
- 37 KB
- Volume
- 10
- Category
- Article
- ISSN
- 1528-8447
No coin nor oath required. For personal study only.